Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Chicago
Study ID
NCT00025389
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — BIOLOGICAL
  • carboplatin — DRUG
  • paclitaxel — DRUG
  • conventional surgery — PROCEDURE
  • neoadjuvant therapy — PROCEDURE

Study Details

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy before surgery may may shrink the tumor so that it can be removed. PURPOSE: This phase II trial is to see if bevacizumab, paclitaxel, and carboplatin given before surgery work in treating patients who have stage IB, stage II, or stage IIIA non-small cell lung cancer.

Key Dates

First listed
Jan 27, 2003
Start date
Nov 30, 2001
Status verified
Feb 2013
Primary completion
Dec 31, 2005
Completion
Aug 31, 2007

Study Design

Enrollment
8 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A
    Bevacizumab (15mg/kg, q3wk x 2), Paclitaxel (200 mg/m2, q3wk x 2), carboplatin (AUC of 6, q3wk x 2), followed by surgery 4 to 6 weeks after last dose of Bevacizumab

Primary Outcome Measure

Response Rate (complete and partial responses by RECIST) [ Time Frame: 4 years ]

Locations (2)

FacilityCityStateZIPSite coordinators
University of Chicago Cancer Research CenterChicagoIllinois60637-1470-
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State UniversityColumbusOhio43210-

Find similar trials in Chicago, IL

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
University of Chicago Cancer Research Center· Chicago, ILArthur G. James Cancer Hospital and Solove Research Institute at Ohio State University· Columbus, OH

Related Studies